Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice.
dc.contributor.author | Han, Junyan | |
dc.contributor.author | Zhong, Jinxin | |
dc.contributor.author | Wei, Wenzhong | |
dc.contributor.author | Wang, Ying | |
dc.contributor.author | Huang, Yafei | |
dc.contributor.author | Yang, Ping | |
dc.contributor.author | Purohit, Sharad | |
dc.contributor.author | Dong, Zheng | |
dc.contributor.author | Wang, Mong-Heng | |
dc.contributor.author | She, Jin-Xiong | |
dc.contributor.author | Gong, Feili | |
dc.contributor.author | Stern, David M. | |
dc.contributor.author | Wang, Cong-Yi | |
dc.contributor.corporatename | Center for Biotechnology and Genomic Medicine | en_US |
dc.contributor.corporatename | Department of Pathology | en_US |
dc.contributor.corporatename | Department of Cellular Biology and Anatomy | en_US |
dc.contributor.corporatename | Department of Physiology | en_US |
dc.date.accessioned | 2010-09-24T20:59:20Z | |
dc.date.available | 2010-09-24T20:59:20Z | |
dc.date.issued | 2008-07-29 | en_US |
dc.description.abstract | OBJECTIVE: The implication of innate immunity in type 1 diabetes development has long been proposed. High-mobility group box 1 (HMGB1), an evolutionarily conserved chromosomal protein, was recently recognized to be a potent innate inflammatory mediator when released extracellularly. We sought to test the hypothesis that HMGB1 acts as an innate immune mediator implicated in type 1 diabetes pathogenesis. RESEARCH DESIGN AND METHODS: Eight- and 12-week-old NOD mice were treated with an HMGB1 neutralizing antibody once a week until 25 weeks of age and monitored for insulitis progression and diabetes onset. The underlying mechanisms of HMGB1 regulation of autoimmune response were further explored. RESULTS: During autoimmunity, HMGB1 can be passively released from damaged pancreatic beta-cells and actively secreted by islet infiltrated immune cells. Extracellular HMGB1 is potent in inducing NOD dendritic cell maturation and stimulating macrophage activation. Blockade of HMGB1 significantly inhibited insulitis progression and diabetes development in both 8- and 12-week-old NOD mice. HMGB1 antibody treatment decreased the number and maturation of pancreatic lymph node (PLN) CD11c(++)CD11b(+) dendritic cells, a subset of dendritic cells probably associated with autoantigen presentation to na??ve T-cells, but increased the number for PLN CD4(+)Foxp3(+) regulatory T-cells. Blockade of HMGB1 also decreased splenic dendritic cell allo-stimulatory capability associated with increased tolergenic CD11c(+)CD8a(+) dendritic cells. Interestingly, the number of CD8(+)interferon-gamma(+) (Tc1) T-cells was increased in the PLNs and spleen after blockade of HMGB1, which could be associated with retarded migration of activated autoreactive T-cells into the pancreatic islets. CONCLUSIONS: Extracellular HMGB1 functions as a potent innate immune mediator contributing to insulitis progression and diabetes onset. | |
dc.identifier.citation | Diabetes. 2008 Aug; 57(8):2118-2127 | en_US |
dc.identifier.doi | 10.2337/db07-1499 | en_US |
dc.identifier.issn | 1939-327X | en_US |
dc.identifier.pmcid | PMC2494682 | en_US |
dc.identifier.pmid | 18477810 | en_US |
dc.identifier.uri | http://hdl.handle.net/10675.2/17 | |
dc.rights | The PMC Open Access Subset is a relatively small part of the total collection of articles in PMC. Articles in the PMC Open Access Subset are still protected by copyright, but are made available under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work. Please refer to the license statement in each article for specific terms of use. The license terms are not identical for all articles in this subset. | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antibodies / immunology / pharmacology | en_US |
dc.subject.mesh | Antigens, CD11c / immunology | en_US |
dc.subject.mesh | Antigens, CD8 / immunology | en_US |
dc.subject.mesh | Autoimmunity / immunology | en_US |
dc.subject.mesh | Blotting, Western | en_US |
dc.subject.mesh | CD8-Positive T-Lymphocytes / drug effects / immunology | en_US |
dc.subject.mesh | Cell Line | en_US |
dc.subject.mesh | Cell Survival / drug effects | en_US |
dc.subject.mesh | Dendritic Cells / drug effects / immunology / metabolism | en_US |
dc.subject.mesh | Diabetes Mellitus, Type 1 / immunology / pathology / prevention & control | en_US |
dc.subject.mesh | Enzyme-Linked Immunosorbent Assay | en_US |
dc.subject.mesh | Flow Cytometry | en_US |
dc.subject.mesh | Forkhead Transcription Factors / metabolism | en_US |
dc.subject.mesh | HMGB1 Protein / genetics / immunology / metabolism | en_US |
dc.subject.mesh | Immunity, Innate / immunology | en_US |
dc.subject.mesh | Insulin-Secreting Cells / cytology / drug effects / metabolism | en_US |
dc.subject.mesh | Interferon-gamma / metabolism | en_US |
dc.subject.mesh | Macrophages / cytology / drug effects / metabolism | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Mice, Inbred C57BL | en_US |
dc.subject.mesh | Mice, Inbred NOD | en_US |
dc.subject.mesh | Recombinant Proteins / pharmacology | en_US |
dc.subject.mesh | Tumor Necrosis Factor-alpha / metabolism | en_US |
dc.title | Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. | en_US |
dc.type | Journal Article | en_US |
dc.type | Research Support, Non-U.S. Gov't | en_US |
html.description.abstract | OBJECTIVE: The implication of innate immunity in type 1 diabetes development has long been proposed. High-mobility group box 1 (HMGB1), an evolutionarily conserved chromosomal protein, was recently recognized to be a potent innate inflammatory mediator when released extracellularly. We sought to test the hypothesis that HMGB1 acts as an innate immune mediator implicated in type 1 diabetes pathogenesis. RESEARCH DESIGN AND METHODS: Eight- and 12-week-old NOD mice were treated with an HMGB1 neutralizing antibody once a week until 25 weeks of age and monitored for insulitis progression and diabetes onset. The underlying mechanisms of HMGB1 regulation of autoimmune response were further explored. RESULTS: During autoimmunity, HMGB1 can be passively released from damaged pancreatic beta-cells and actively secreted by islet infiltrated immune cells. Extracellular HMGB1 is potent in inducing NOD dendritic cell maturation and stimulating macrophage activation. Blockade of HMGB1 significantly inhibited insulitis progression and diabetes development in both 8- and 12-week-old NOD mice. HMGB1 antibody treatment decreased the number and maturation of pancreatic lymph node (PLN) CD11c(++)CD11b(+) dendritic cells, a subset of dendritic cells probably associated with autoantigen presentation to na??ve T-cells, but increased the number for PLN CD4(+)Foxp3(+) regulatory T-cells. Blockade of HMGB1 also decreased splenic dendritic cell allo-stimulatory capability associated with increased tolergenic CD11c(+)CD8a(+) dendritic cells. Interestingly, the number of CD8(+)interferon-gamma(+) (Tc1) T-cells was increased in the PLNs and spleen after blockade of HMGB1, which could be associated with retarded migration of activated autoreactive T-cells into the pancreatic islets. CONCLUSIONS: Extracellular HMGB1 functions as a potent innate immune mediator contributing to insulitis progression and diabetes onset. | |
refterms.dateFOA | 2019-04-09T16:32:11Z |
Files
Original bundle
1 - 1 of 1